Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib

Abed Agbarya, Meira Melamed-Frank, Orit Kaidar-Person, Ilana Goldberg-Cohen, Haitam Nasrallah, Mira Wollner, Jair Bar, Gad Rennert, Flavio Lejbkowicz

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Most patients with non-small cell lung cancer (NSCLC) present with advanced disease and have poor long-term prognosis. Advanced NSCLC that contains characteristic mutations in epidermal growth factor receptor (EGFR) are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs). EGFR exon 19 insertions mutations are rare, and response to TKIs is still unclear. Case description: A young Arab patient was diagnosed with metastatic disease of NSCLC harboring an exon 19 insertion of 18 nucleotides. The patient showed a very impressive clinical and radiological response within few weeks treatment with TKI agent. Discussion and evaluation: To our best knowledge, This case is the first case in Arab woman and one of few cases described in the literature with this rare mutation responding to TKIs. Conclusions: Treatment with TKIs should be the standard choice in patients with metastatic disease NSCLC.

Original languageEnglish
Article number507
JournalSpringerPlus
Volume3
Issue number1
DOIs
StatePublished - 30 Dec 2014
Externally publishedYes

Keywords

  • Epidermal growth factor receptor
  • Erlotinib
  • Exon 19 insertion
  • Non-small cell lung cancer

Fingerprint

Dive into the research topics of 'Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib'. Together they form a unique fingerprint.

Cite this